A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability
Open Access
- 1 May 2014
- journal article
- clinical trial
- Published by Elsevier in Genetics in Medicine
- Vol. 16 (5) , 359-366
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double‐blind, multinational, Phase 3 studyAmerican Journal of Hematology, 2013
- An evidence-based review of the potential benefits of taliglucerase alfa in the treatment of patients with Gaucher diseaseCore Evidence, 2012
- Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: Early Access Program results from JerusalemBlood Cells, Molecules, and Diseases, 2012
- Pivotal trial with plant cell–expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher diseaseBlood, 2011
- Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher diseaseJournal of Immunological Methods, 2011
- Gaucher disease: clinical profile and therapeutic developmentsBiologics: Targets and Therapy, 2010
- Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experienceBlood, 2010
- A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1Molecular Genetics and Metabolism, 2009
- Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)Human Mutation, 2008
- The long-term international safety experience of imiglucerase therapy for Gaucher diseaseMolecular Genetics and Metabolism, 2007